Reasons to Add Penumbra Stock to Your Portfolio Now

Zacks01-07 19:44

Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501029012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 19:44","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501029012","market":"us","top_or_hot":-1,"title":"Reasons to Add Penumbra Stock to Your Portfolio Now","media":"Zacks","content":"<div>\n<p>Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-add-penumbra-stock-portfolio-114400407.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reasons to Add Penumbra Stock to Your Portfolio Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReasons to Add Penumbra Stock to Your Portfolio Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/reasons-add-penumbra-stock-portfolio-114400407.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming...</p>\n\n<a href=\"https://finance.yahoo.com/news/reasons-add-penumbra-stock-portfolio-114400407.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2008162690.USD","symbol_name":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/reasons-add-penumbra-stock-portfolio-114400407.html","article_id":"2501029012","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501029012","pubTimestamp":1736250240,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming years. A robust solvency position also bodes well for the stock. Meanwhile, unfavorable foreign exchange remains a concern for Penumbra.In the past six months, shares of this Zacks Rank #2  company have rallied 32.4% compared with the industry’s 0.3% growth and the S&P 500 composite’s 6.8% gain.The global healthcare provider has a market capitalization of $9.29 billion. PEN beat on earnings in three of the trailing four quarters and missed in one, the average surprise being 10.54%.Foreign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost o","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4139":"生物科技","PEN":"Penumbra Inc","OMCL":"Omnicell","BK4588":"碎股","BK4504":"桥水持仓","BK4167":"医疗保健技术","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","RMD":"瑞思迈","BK4548":"巴美列捷福持仓","VCYT":"Veracyte Inc","BK4082":"医疗保健设备","BK4567":"ESG概念","BK4585":"ETF&股票定投概念"},"translate_title":"立即将Penumbra股票添加到您的投资组合的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1,"PEN":1,"RMD":1,"VCYT":1},"content_text":"Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming years. A robust solvency position also bodes well for the stock. Meanwhile, unfavorable foreign exchange remains a concern for Penumbra.  \nIn the past six months, shares of this Zacks Rank #2 (Buy) company have rallied 32.4% compared with the industry’s 0.3% growth and the S&P 500 composite’s 6.8% gain.\nThe global healthcare provider has a market capitalization of $9.29 billion. PEN beat on earnings in three of the trailing four quarters and missed in one, the average surprise being 10.54%.\nTailwinds for Penumbra\nRobust Thrombectomy Business Growth: Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In the third quarter of 2024, the company delivered 21.2% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 32% year over year.\nGlobal Expansion Continues: Penumbra derives a significant portion of its revenues internationally. The company expects to materially increase revenues and profitability in its international business in the next three years and beyond. \nInternationally, the company projects early success with the launch of its first-generation computer-aided products in Europe. In addition, PEN’s international teams and partners envision enormous potential to further expand its leadership in stroke intervention outside the United States with SENDit and Thunderbolt over the coming years. Per the latest update, the company received the CE Mark for Lightning Flash 2.0 and Lightning Bolt 7 in mid-September 2024 and is in the early phases of introducing its transformative technology to European markets. \nStable Solvency Structure: Penumbra exited the third quarter of 2024 with cash and cash equivalents of $291 million. Meanwhile, total debt was $22 million, much lower than the corresponding cash and cash equivalent level. Also, it has no short-term-payable debt on its balance sheet. This is good news in terms of the company’s solvency position, particularly during global inflation and supply delays.\nImage Source: Zacks Investment Research\nHeadwinds for Penumbra\nForeign Exchange Impacts Sales: A significant portion of Penumbra’s sales and costs is exposed to changes in foreign exchange rates. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses, and consequently, net income.\nPEN Stock Estimate Trends\nIn the past 30 days, the Zacks Consensus Estimate for Penumbra’s 2025 earnings has remained unchanged at $3.86. \nThe Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $1.37 billion, indicating a 14.9% rise from the year-ago reported number. \nOther Top MedTech Stocks\nSome other top-ranked stocks in the broader medical space are Veracyte VCYT, Omnicell OMCL and ResMed RMD.\nVeracyte's estimated 2025 earnings growth rate is 65.8%, compared with the industry’s 21.9%. Its shares have risen 49.2% in the past year, compared with the industry’s 5.5% growth. VCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. \nVCYT carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nOmnicell, carrying a Zacks Rank #2 at present, has an earnings yield of 3.7% compared with the industry’s 9.5%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 121.74%. OMCL’s shares have risen 15.2% against the industry’s 16.8% decline in the past year.\nResMed, carrying a Zacks Rank 2 at present, has an estimated earnings growth rate of 8.9% for fiscal 2025. Its shares have surged 33.4% compared with the industry’s 11.1% growth in the past year. RMD’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 6.41%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501029012"}